This text is a result of machine translation.
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Several new funds have actively picked up chips to speed up the pace of position building
Guo Xiaohe, member of the Party group and deputy director of Henan public resources trading center, was examined and investigated
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
US regulators say they are actively seeking to reach a cooperation agreement with China to end years of cross-border audit and supervision dilemma
Last year, the data on the scale of private placement of securities companies came out, and CICC soared by more than 600 billion a year, directly catching up with CITIC
The Real Bottleneck in Embodied AI: Not Just AI, but Scenarios
Apr 07, 2026 06:52 PM
Investment Is Booming, Orders Are Rising, but Robots Are Still Learning How to Deliver
Mar 23, 2026 10:29 AM
Thinking of ASEAN as a single market is the biggest miscalculation for Chinese companies
Feb 19, 2026 12:00 PM